ABSTRACT
Primary age-related tauopathy (PART) is characterized by the presence of tau neurofibrillary tangles (NFTs) which are typically observed in Alzheimer's disease (AD) brains, with few or without β-amyloid (Aβ) plaques. The diagnosis of PART can be categorized into "definite" or "possible" depending on the amount of Aβ plaques. Definite PART is diagnosed when NFTs are observed and the Braak stage is ≤IV, with Thal Aβ Phase 0 (Crary et al., 2014). According to the neuropathological diagnostic criteria, we reported that PART was frequently observed in the Chinese population according to our findings from specimens in our brain bank, with 47% of brain bank subjects meeting the criteria for PART. There is no consensus on the nature of PART. It remains to be elucidated whether PART is an early form of AD or a novel tauopathy (Duyckaerts et al., 2015; Jellinger et al., 2015).
Subject(s)
Aged , Aged, 80 and over , Female , Humans , Male , Middle Aged , Aging/pathology , Alzheimer Disease/pathology , Brain/pathology , Cohort Studies , Neurofibrillary Tangles/pathology , Tauopathies/pathologyABSTRACT
Neuronal histamine is crucially involved in a number of physiological functions as well as in neuropsychiatric diseases. Determination of histamine in biological samples is thus of importance in the clinical studies. The aim of this review is to summarize the progress or effort made in this field, with focus on the high-performance liquid chromatography.
Subject(s)
Humans , Chromatography, High Pressure Liquid , Methods , Histamine , Cerebrospinal FluidABSTRACT
<p><b>OBJECTIVE</b>To evaluate the changes of plasma levels of the excitatory amino acid neurotransmitter aspartic acid (Asp), inhibitory neurotransmitter glycine (Gly) and asparagine (Asn) in patients with major depressive disorder (MDD).</p><p><b>METHODS</b>Plasma samples were collected from 15 MDD patients (9 males and 6 females, aged 32-64 y) and 14 healthy subjects (7 males and 7 females, aged 30-65 y); and also collected from 7 MDD patients (5 males and 2 females) 2 months after antidepressant treatment. The plasma levels of amino acids were determined by high performance liquid chromatography with fluorescence detection method.</p><p><b>RESULTS</b>Plasma Asp and Gly levels were significantly lower in MDD patients than those in controls (P<0.04). There were positive correlations between plasma levels of Gly and Asp, and between Gly and Asn (P<0.005) in the control group; while in MDD patients, a significant positive correlation was found only between plasma levels of Gly and of Asp (P<0.001). MDD patients did not show significant changes in plasma Asp, Asn and Gly levels after antidepressant treatment compared to those before treatment.</p><p><b>CONCLUSION</b>The reduced plasma Asp and Gly levels may serve as a clinical biomarker for MDD.</p>